Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.48 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4103018 | 0.81 | HTT (0.51) | SMN1; SMN2NTRK1ALDH1A1 | |
| SCHEMBL4508129 | 0.80 | KDM4E (0.48) | SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL27312106 | 0.79 | SMN1; SMN2 (0.55) | SMN1; SMN2RAB9ANPC1NTRK1NTRK3 | |
| SCHEMBL30877023 | 0.79 | SMN1; SMN2 (0.55) | SMN1; SMN2RAB9ANPC1NTRK1NTRK3 | |
| SCHEMBL4102925 | 0.78 | FES (0.52) | SMN1; SMN2KMT2AL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL4108710 | 0.77 | RAB9A (0.50) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL4114519 | 0.77 | CA12 (0.49) | RAB9ANPC1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL29460273 | 0.77 | SMN1; SMN2 (0.79) | SMN1; SMN2RAB9ANPC1ALOX15KMT2A | |
| SCHEMBL21065524 | 0.77 | SMN1; SMN2 (0.79) | SMN1; SMN2RAB9ANPC1ALOX15KMT2A | |
| SCHEMBL4108478 | 0.77 | CA12 (0.52) | RAB9AKMT2AL3MBTL1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078716-A1 | New derivatives of 1H-indol-1-yl-urea, method for preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2009-07-15 | — | — | EP | disclosed |
| US-20090176794-A1 | 1H-INDOL-1-YL-UREA COMPOUNDS | LES LABORATOIRES SERVIER (FR) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176794-A1 | 1H-INDOL-1-YL-UREA COMPOUNDS | TPH1, HTR1D, IDO1 | SMN1; SMN2 269/4885RAB9A 1050/4885NPC1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.